Cargando…
TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial
BACKGROUND: TRC150094, a novel mitochondrial modulator, reduces insulin resistance and is expected to improve the trinity of dysglycemia, dyslipidemia, and hypertension. In this multi-dose phase-2 study, we evaluated the safety and efficacy of TRC150094 in diabetic subjects with dyslipidemia receivi...
Autores principales: | Joshi, Deepa, GJ, Prashant, Ghosh, Shohini, Mohanan, Anookh, Joshi, Shashank, Mohan, Viswanathan, Chowdhury, Subhankar, Dutt, Chaitanya, Tandon, Nikhil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887612/ https://www.ncbi.nlm.nih.gov/pubmed/35241920 http://dx.doi.org/10.2147/DMSO.S330515 |
Ejemplares similares
-
Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial
por: Joshi, Deepa, et al.
Publicado: (2021) -
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
por: Zambad, Shitalkumar P, et al.
Publicado: (2011) -
TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats
por: Mohanan, Anookh, et al.
Publicado: (2011) -
Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries
por: Dutt, Chaitanya, et al.
Publicado: (2022) -
TRC: Mission Accomplished
por: Hood, Ernie
Publicado: (2007)